98 related articles for article (PubMed ID: 17462257)
1. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.
Fomin P; Beuran M; Gradauskas A; Barauskas G; Datsenko A; Dartois N; Ellis-Grosse E; Loh E;
Int J Surg; 2005; 3(1):35-47. PubMed ID: 17462257
[TBL] [Abstract][Full Text] [Related]
2. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections.
Towfigh S; Pasternak J; Poirier A; Leister H; Babinchak T
Clin Microbiol Infect; 2010 Aug; 16(8):1274-81. PubMed ID: 20670293
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Dartois N; Castaing N; Gandjini H; Cooper A;
J Chemother; 2008 Oct; 20 Suppl 1():28-35. PubMed ID: 19036672
[TBL] [Abstract][Full Text] [Related]
10. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial.
Qvist N; Warren B; Leister-Tebbe H; Zito ET; Pedersen R; McGovern PC; Babinchak T
Surg Infect (Larchmt); 2012 Apr; 13(2):102-9. PubMed ID: 22439781
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.
Chen Z; Wu J; Zhang Y; Wei J; Leng X; Bi J; Li R; Yan L; Quan Z; Chen X; Yu Y; Wu Z; Liu D; Ma X; Maroko R; Cooper A
BMC Infect Dis; 2010 Jul; 10():217. PubMed ID: 20663130
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.
Chen Y; Zhu D; Zhang Y; Zhao Y; Chen G; Li P; Xu L; Yan P; Hickman MA; Xu X; Tawadrous M; Wible M
Ther Clin Risk Manag; 2018; 14():2327-2339. PubMed ID: 30584308
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
Jenkins SG; Fisher AC; Peterson JA; Nicholson SC; Kaniga K
Curr Med Res Opin; 2009 Dec; 25(12):3029-36. PubMed ID: 19849650
[TBL] [Abstract][Full Text] [Related]
19. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Breedt J; Teras J; Gardovskis J; Maritz FJ; Vaasna T; Ross DP; Gioud-Paquet M; Dartois N; Ellis-Grosse EJ; Loh E;
Antimicrob Agents Chemother; 2005 Nov; 49(11):4658-66. PubMed ID: 16251309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
